Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

80 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Diabetic retinopathy should not be a contraindication to thrombolytic therapy for acute myocardial infarction: review of ocular hemorrhage incidence and location in the GUSTO-I trial. Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries.
Mahaffey KW, Granger CB, Toth CA, White HD, Stebbins AL, Barbash GI, Vahanian A, Topol EJ, Califf RM. Mahaffey KW, et al. Among authors: barbash gi. J Am Coll Cardiol. 1997 Dec;30(7):1606-10. doi: 10.1016/s0735-1097(97)00394-x. J Am Coll Cardiol. 1997. PMID: 9385883 Free article. Clinical Trial.
Neurosurgical evacuation of intracranial hemorrhage after thrombolytic therapy for acute myocardial infarction: experience from the GUSTO-I trial. Global Utilization of Streptokinase and tissue-plasminogen activator (tPA) for Occluded Coronary Arteries.
Mahaffey KW, Granger CB, Sloan MA, Green CL, Gore JM, Weaver WD, White HD, Simoons ML, Barbash GI, Topol EJ, Califf RM. Mahaffey KW, et al. Among authors: barbash gi. Am Heart J. 1999 Sep;138(3 Pt 1):493-9. doi: 10.1016/s0002-8703(99)70152-3. Am Heart J. 1999. PMID: 10467200 Clinical Trial.
Early reinfarction after fibrinolysis: experience from the global utilization of streptokinase and tissue plasminogen activator (alteplase) for occluded coronary arteries (GUSTO I) and global use of strategies to open occluded coronary arteries (GUSTO III) trials.
Hudson MP, Granger CB, Topol EJ, Pieper KS, Armstrong PW, Barbash GI, Guerci AD, Vahanian A, Califf RM, Ohman EM. Hudson MP, et al. Among authors: barbash gi. Circulation. 2001 Sep 11;104(11):1229-35. doi: 10.1161/hc3601.095717. Circulation. 2001. PMID: 11551872
Evaluation of paradoxic beneficial effects of smoking in patients receiving thrombolytic therapy for acute myocardial infarction: mechanism of the "smoker's paradox" from the GUSTO-I trial, with angiographic insights. Global Utilization of Streptokinase and Tissue-Plasminogen Activator for Occluded Coronary Arteries.
Barbash GI, Reiner J, White HD, Wilcox RG, Armstrong PW, Sadowski Z, Morris D, Aylward P, Woodlief LH, Topol EJ. Barbash GI, et al. J Am Coll Cardiol. 1995 Nov 1;26(5):1222-9. doi: 10.1016/0735-1097(95)00299-5. J Am Coll Cardiol. 1995. PMID: 7594035 Free article. Clinical Trial.
Variations in patient management and outcomes for acute myocardial infarction in the United States and other countries. Results from the GUSTO trial. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries.
Van de Werf F, Topol EJ, Lee KL, Woodlief LH, Granger CB, Armstrong PW, Barbash GI, Hampton JR, Guerci A, Simes RJ, et al. Van de Werf F, et al. Among authors: barbash gi. JAMA. 1995 May 24-31;273(20):1586-91. doi: 10.1001/jama.273.20.1586. JAMA. 1995. PMID: 7745771 Clinical Trial.
80 results